GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Inventiva Sa IVA · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.84

+1.05%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Inventiva Sa

Its shares trade under the ticker IVA. It has been listed since 10 July 2020. In the fiscal year to 31 December 2025, it reported revenue of $5.1m and a net loss of $401.6m. At that date it held total assets of $283.0m and shareholders' equity of −$32.3m.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
10 Jul 2020
Employees
77
Head office
50 RUE DE DIJON, DAIX, I0, 21121
Incorporated in
I0
Classification
Pharmaceutical Preparations
Filer status
Accelerated filer

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Company is focused on clinical-stage biopharmaceutical development.
  • Develops multiple therapies including Lanifibranor for MASH treatment.
  • Headquartered in Daix, France with a clear focus on metabolic diseases.

Weaknesses

  • Company is clinical-stage with no approved products yet.
  • Relies on a single Phase 3 trial for Lanifibranor as a major product.
  • Limited employee count of 77 may impact operational capacity.

Opportunities

  • Potential market for MASH treatments as the disease prevalence increases.
  • Expansion of Lanifibranor into other therapeutic areas beyond MASH.
  • International growth opportunities in the health care sector.

Threats

  • Failure of Phase 3 trial for Lanifibranor could significantly impact the company.
  • Competition in the MASH treatment market may reduce market share.
  • Regulatory hurdles could delay or prevent product approvals.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.